Analyzing China Dongsheng International (OTCMKTS:CDSG) & Amarin (NASDAQ:AMRN)

Amarin (NASDAQ:AMRN) and China Dongsheng International (OTCMKTS:CDSG) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, analyst recommendations and earnings.

Analyst Ratings

This is a summary of recent ratings and price targets for Amarin and China Dongsheng International, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarin	1	1	1	0	2.00
China Dongsheng International	0	0	0	0	N/A

Amarin presently has a consensus target price of $1.00, suggesting a potential upside of 65.51%. Given Amarin’s higher possible upside, equities analysts clearly believe Amarin is more favorable than China Dongsheng International.

Valuation & Earnings

This table compares Amarin and China Dongsheng International”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarin	$264.78 million	0.94	-$59.11 million	($0.12)	-5.04
China Dongsheng International	N/A	N/A	-$100,000.00	N/A	N/A

China Dongsheng International has lower revenue, but higher earnings than Amarin.

Profitability

This table compares Amarin and China Dongsheng International’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Amarin	-12.66%	-6.09%	-4.11%
China Dongsheng International	N/A	N/A	N/A

Insider & Institutional Ownership

22.3% of Amarin shares are owned by institutional investors. 2.0% of Amarin shares are owned by company insiders. Comparatively, 73.5% of China Dongsheng International shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility and Risk

Amarin has a beta of 1.92, indicating that its stock price is 92% more volatile than the S&P 500. Comparatively, China Dongsheng International has a beta of 15.25, indicating that its stock price is 1,425% more volatile than the S&P 500.

Summary

China Dongsheng International beats Amarin on 6 of the 10 factors compared between the two stocks.

About Amarin

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

About China Dongsheng International

China Dongsheng International, Inc. engages in the acquisition, exploration, and development of mineral properties. The company primarily explores for lithium. It holds an 80% interest in the Titan Projects located in Tanzania; and has right to earn 60% interest in the West End Lithium Project near Tonopah Nevada. China Dongsheng International, Inc. is based in Las Vegas, Nevada.